IC
TGTX icon

Ikarian Capital’s TG Therapeutics TGTX Stock Holding History

Ikarian Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-826,100
Closed -$20.5M – 171
2023
Q2 		$20.5M Buy
+826,100
New +$21.3M 3.27% 6
2022
Q1 		– Sell
-98,600
Closed -$1.87M – 212
2021
Q4 		$1.87M Hold
98,600
– – 0.28% 69
2021
Q3 		$3.28M Sell
98,600
-1,400
-1% -$43.3K 0.23% 97
2021
Q2 		$3.88M Hold
100,000
– – 0.31% 79
2021
Q1 		$4.82M Hold
100,000
– – 0.16% 120
2020
Q4 		$5.2M Buy
+100,000
New +$3.38M 0.23% 91

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ikarian Capital's TGTX Position: Q1 2026 in Review

Ikarian Capital sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 117,903 shares — an estimated $3.51M sold.

Ikarian Capital first reported a position in TGTX in Q4 2019 and held it in 9 quarters. The position peaked at $8.77M in Q4 2024. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Ikarian Capital reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 117,903 TG Therapeutics shares in Q1 2026, an estimated $3.51M.
  • Ikarian Capital first reported a position in TG Therapeutics in Q4 2019 and held it in 9 quarters.
  • Ikarian Capital's TG Therapeutics position peaked at $8.77M in Q4 2024.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.